The best response to fibrinolytic drugs is within a couple of hours, before the fibrin meshwork of the thrombus has been fully developed. Organization and recanalization involves the ingrowth of smooth muscle cells, fibroblasts and endothelium into the fibrin-rich thrombus. If recanalization proceeds it provides capillary-sized channels through the thrombus for continuity of blood flow through the entire thrombus but may not restore sufficient blood flow for the metabolic needs of the downstream tissue. See also
Thrombogenicity (the tendency to clot)
National Blood Clot Alliance
Hemorrhoid

References
External links

Muscle Relaxing Drugs Can Reduce Lethal Blood Clots Archived 2009-02-04 at the Wayback Machine
Air Pollution Triggers Blood Clots - US Study.
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Developed by Global Blood Therapeutics, voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity.In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those twelve years of age and older. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. In December 2021, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those aged four to eleven years. Side effects
Common side effects include headache, diarrhea, abdominal pain, nausea, fatigue, rash and pyrexia (fever). History
Voxelotor was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2019. The FDA granted the application for voxelotor fast track designation and orphan drug designation.The approval of voxelotor was based on the results of a clinical trial with 274 participants with sickle cell disease.The FDA granted the approval of Oxbryta to Global Blood Therapeutics.